Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial
    Meeting Abstract

    Hochhauser, D.; Kindler, H.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Arnold, D.; Oh, D. Y.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis
    Meeting Abstract

    Krebs, M. G.; De Braud, F.; Siena, S.; Drilon, A.; Doebele, R. C.; Patel, M. R.; Cho, B. C.; Liu, S. V.; Ahn, M. J.; Chiu, C. H.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline
    Meeting Abstract

    Dziadziuszko, R.; Siena, S.; Tan, D. S. W.; Cho, B. C.; Ahn, M. J.; Goto, K.; Garrido-Lopez, P.; Farago, A. F.; Loong, H. H. F.; Tosi, D.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Meeting Abstract

    Drilon, A.; Moreno, V.; Patel, J.; Lassen, U. N.; Solomon, B.; Rosen, L.; Leyvraz, S.; Tan, D. S. W.; Reeves, J. A.; Dima, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion + non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gautschi, O.; Drilon, A.; Tan, D. S. W.; Oxnard, G. R.; McCoach, C.; Goto, K.; Park, K.; Alonso Casal, G.; de Braud, F.; French, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Mazieres, J.; Tomasini, P.; Lusque, A.; Boucekine, M.; Gautschi, O.; Cortot, A. B.; Couraud, S.; Thai, A.; Ng, T.; Greillier, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A
    Meeting Abstract

    Mazieres, J.; Paik, P. K.; Felip, E.; Veillon, R.; Sakai, H.; Cortot, A. B.; Viteri, S.; Garassino, M. C.; Van Meerbeeck, J. P.; Raskin, J.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Viteri, S.; Mazieres, J.; Veillon, R.; Felip, E.; Le, X.; Garassino, M. C.; Stanton, T. S.; Morise, M.; Lee, J. S.; Matsumoto, S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Suboptimal real-world (RW) outcomes for BRAF+ metastatic melanoma (MM) patients in 2L therapy (The NOBLE study series)
    Meeting Abstract

    Tarhini, A. A.; Betof Warner, A.; Johnson, M.; Kang, B.; Nakasato, A.; Vance, M.; Ling, Y. L.; Tang, J.; Patel, J.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma
    Meeting Abstract

    Hamid, O.; Joshua, A. M.; Hwu, W. J.; Ribas, A.; Weber, J.; Daud, A. S.; Hodi, F. S.; Wolchok, J. D.; Mitchell, T. C.; Hersey, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save